The U.S giant drugmaker Pfizer and BioNTech SE has announced its analysis for COVID-19 vaccine Phase – 3 trial. It was found 95% effective in the final analysis of the Phase-3 mRNA-based COVID-19 vaccine trial.
The results have come out after the second dose of vaccine, during trials its observed that efficacy in adults over 65 years of age was over 94%
The drug maker says that the study reached 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. Efficacy was consistent across age, gender observed adults over 65 years of age was over 94%.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus forward share with regulators around the world.” Said Dr Albert Bourla , Pfizer Chairman and CEO
The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021, Pfizer said in a statement
